Hypertension in end-stage renal disease patients

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 3, 2000, Pages 279-283

  Zager, Philip ^a,b   Nikolic, Jovanka ^b   Raj, Dominic S C ^c   Tzamaloukas, Antonios ^d   Campbell, Marilyn ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b Dialysis Clinic Inc   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; LOSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORTALITY; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW;

HUMANS; HYPERTENSION; KIDNEY FAILURE; PREVALENCE; RANDOMIZED CONTROLLED TRIALS;

EID: 0034119635     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200005000-00012     Document Type: Review

References (54)

1. 1 JNC VI. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Sixth Report. Arch Intern Med 1997; 157:2413-2445.
2. 2 Meissner I, Whisnant JP, Sheps SG, Schwartz GL, O'Fallon WM, Covalt JL, et al. Detection and control of high blood pressure in the community: Do we need a wake-up call? Hypertension 1999; 34:466-471.
3. 3 Swales JD. Current status of hypertensive disease treatment: results from the Evaluation and Interventions for Systolic Blood Pressure Elevation: Regional and Global (EISBERG) project. J Hypertens 1999; 17:(suppl 2):S15-S19.
4. 4 Staessen JA, Thijs L, Fagard RH, Birkenhager WH, Arbidze G, Babeanu S, et al. Calcium channel blockade and cardiovascular prognosis in the European Trial on Isolated Systolic Hypertension. Hypertension 1998; 32:410-416.
5. 5 Staessen JA, Thijs L, Gasowski J, Cells H, Fagard R. Treatment of isolated systolic hypertension in the elderly: further evidence from the Systolic Hypertension in Europe (Syst_Eur) Trial (for the Systolic hypertension in Europe Trial Investigators). Am J Cardiol 1998; 82:20R-22R. Demonstrates that treatment of isolated systolic hypertension in the elderly persons decreases the risk for stroke and CVD.
6. 6 Hansson L, Zanchetti A, Carruthres SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762. Important study which demonstrates the beneficial effect of lowering diastolic blood pressure to 82 ± 86 mmHg.
7. 7 Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32:853-906. Important policy statement containing clinical recommendations from the National Kidney Foundation's task force on CVD.
8. 8 USRDS, U.S. Renal Data System, USRDS 1999 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999. Comprehensive data analysis on Medicare eligible end-stage renal disease population.
9. 9 Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47:186-192.
10. 10 Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84:985-992.
11. 11 Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttman RD. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 60:908-914.
12. 12 Foley RN, Parfrey PS, Sarnak MJ. Cardiovascular disease in chronic renal disease: clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3):S112-S119. Important review of clinical epidemiology of CVD in chronic renal disease. The paper contains useful clinical recommendations.
13. 13 Rahman M, Dixit A, Donley V, Gupta S, Hanslik T, Lacson E, et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 1999; 33:498-506. Hypertension was associated with interdialytic weight gain, as a primary cause of end-stage renal disease, and with shorter duration of end-stage renal disease.
14. 14 Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6:184-191.
15. 15 Fenton S, Schaubel D, Desmeules M, Morrison H, Mao Y, Copleston P, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997; 30:334-342.
16. 16 Foley RN, Parfrey PS, Harnett JD, Kent GM, O'Dea R, Murray DC, Barre PE. Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 1998; 9:267-276.
17. 17 Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54:1720-1725. Prospective longitudinal study of echocardiographic findings in dialysis patients.
18. 18 Murphy SW, Foley RN, Parfrey PS. Screening and treatment for cardiovascular disease in patients with chronic renal failure. Am J Kidney Dis 1998; 32 (Suppl. 3):S184-S199. Important review which contains useful recommendations for screening and treatment of CVD.
19. 19 Levy D, Salomon M, D'Agostino R, Belanger A, Kannel W. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
20. 20 Yuranev AP, Dyakonaova HG, Novikov ID, Vitols A, Pahl L, Haynemann G, et al. Management of essential hypertension in patients with different degrees of LVH: multicenter trial. Am J Hypertens 1990; 3:512-517.
21. 21 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
22. 22 Vertes V, Cangiano J, Berman L, Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969; 280:978-981.
23. 23 Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3):S120-S141. Reviews clinical epidemiology of CVD in patients with chronic renal disease. It also contains clinical recommendations based on JNC VI and NKF's task force on CVD reports.
24. 24 Wizemann V, Kramer W. Short-term dialysis - long term complications: ten year experience with short duration renal replacement therapy. Blood Purif 1987; 5:193-201.
25. 25 Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286-1291.
26. 26 Charra B, Calemard E, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996; 16:35-44.
27. 27 Chazot C, Charra B, Laurent G, Didier C, Vo Van C, Terrat JC, et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995; 10:831-837.
28. 28 Charra B, Laurent G, Chazot C, Calemard E, Terrat JC, Vanel T, et al. Clinical assessment of dry weight. Nephrol Dial Transplant 1996; 11 (Suppl. 2):16-19.
29. 29 Charra B, Bergstrom J, Scribner BH. Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 1998; 32:720-724. Important report which increases understanding of dry weight and blood pressure control.
30. 30 Woods JD, Port FK, Orzol S, Buoncristiani U, Young E, Wolfe RA, Held PJ. Clinical and biochemical correlates of starting 'daily' hemodialysis. Kidney Int 1999; 55:2467-2476. Important observations on the effect of DHD on HTN control.
31. 31 Buoncristiani U, Quitaliani G, Cozzari M, Giombini L, Ragaiolo M. Daily dialysis: long-term clinical metabolic results. Kidney Int 1988; Suppl. 24:S137-S140.
32. 32 Mastrangelo F, Alfonso M, Napoli V, DeBlasi V, Russo F, Patruno P. Dialysis with increased frequency of sessions (Lecce dialysis). Nephrol Dial Transplant 1998; 13 (Suppl. 6):139-147.
33. 33 Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9:899-900.
34. 34 Zoccali C, Benedetto FA, Tripepi G, Cambareri F, Panuccio V, Candela V, et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int 1998; 53:1078-1084. Important observation that nocturnal hypoxemia is associated with a non-dipping arterial pressure profile in dialysis patients.
35. 35 Buoncristiani U, Fagugli RM, Pinciaroli MR, Kulurianu H, Ceravolo G, Bova C. Reversal of left-ventricular hypetrophy in uremic patients by treatment with daily hemodialysis (DHD). Contrib Nephrol 1996; 119:152-156.
36. 36 Buoncristiani U, Fagugli RM, Ciao G, Pasticci F, Pasini P, Cicconi B, et al. Left ventricle hypertrophy reduction in hypertensive patients on daily hemodialysis [abstract]. J Am Soc Nephrol 1998; 9:232A.
37. 37 Covic A, Goldsmith DJA, Georgescu G, Venning MC, Ackrill P. Echocardiographic findings in long-term, long-hour hemodialysis patients. Clin Nephrol 1996; 45:104-110.
38. 38 Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, et al. 'U' curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54:561-569.
39. 39 Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LYC, Young EW. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33:507-517. Reports elevated mortality risk associated with low predialysis systolic blood pressure.
40. 40 Salem MM, Bower J. Hypertension in the hemodialysis population: any relation to one-year survival? Am J Kidney Dis 1996; 28:737-740.
41. 41 Salem MM. Hypertension in the haemodialysis population: any relationship to 2-years survival? Nephrol Dial Transplant 1999; 14:125-128. Surprising observation that hypertensive dialysis patients had a two-year survival at least as high as that observed in normotensive dialysis patients.
42. 42 Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999; 55:1528-1535. Novel approach to treating hypertension in noncompliant hypertensive hemodialysis patients.
43. 43 Albitar S, Genin R, Fen-Chong M, Serveaux M-O, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13:1206-1210.
44. 44 Pegues D, Beck-Sague C, Woolen S, Greenspan B, Burns SM, Bland LA, et al. Analphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 1992; 42:1232-1237.
45. 45 Tielemans C, Goldman M, Vanherweghem J. Immediate hypersensitivity reactions and hemodialysis. Adv Nephrol Necker Hosp 1993; 22:401-416.
46. 46 Cocchi R, Esposti ED, Fabbri A, Lucatello A, Sturani A, Quarello F, et al. Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study. Nephrol Dial Transplant 1999; 14:1536-1540. Important study documenting high prevalence of hypertension in patients with peritoneal dialysis. It includes a comparison of office blood pressure with ambulatory blood pressure monitoring.
47. 47 Takeda K, Nakamoto M, Baba M, Tanaka T, Yasunaga C, Nishihara G, et al. Echocardiographic evaluation in long-term continuous ambulatory peritoneal dialysis compared with the hemodialysis patients. Clin Nephrol 1998; 49:308-312. Left ventricular hypertrophy and cardiac dysfunction are progressive in patients with peritoneal dialysis.
48. 48 Lang SM, Wolfram G, Gerzer R, Schiffl H. Characterization of subtypes of hypertension in CAPD patients by cyclic guanosine monophosphate. Perit Dial Int 1999; 19:143-147. Describes relationship of plasma cGMP levels to volume and blood pressure in patients with peritoneal dialysis.
49. 49 Dumler F. Total body water content in peritoneal dialysis patients: comparison to the National Health and Nutritional Examination Survey (NHANES) III [abstract]. Perit Dial Int 2000:(in press).
50. 50 Plum J, Schoenicke J, Grabensee B. Body fluid distribution and serum albumin in dialysis patients. Comparison between hemodialysis and peritoneal dialysis. Perit Dial Int (Abstract), (in press).
51. 51 Opelz G, Wujciak T, Ritz Eft CTS. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53:217-222. Presents evidence that controlled blood pressure is a significant predictor of long-term graft function.
52. 52 Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn K-H. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33:862-868. Documents safety and efficacy of angiotensin converting enzyme inhibitors in renal transplant recipients.
53. 53 del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Pereira P, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998; 54 (Suppl. 86):S135-S139. Documents safety and efficacy of angiotensin II receptor antagonists in hypertensive renal transplant recipients.
54. 54 Martinez-Castelao A, Hueso M, Sanz V, Rejas J, Alsina J, Grinyo JM. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int 1998; 54 (Suppl. 86):S130-S134.